A retrospective study of low doses of nivolumab plus ipilimumab combined with IL-2 and hyperthermia in cancer patients
Latest Information Update: 19 May 2021
At a glance
- Drugs Aldesleukin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Taurolidine
- Indications Advanced breast cancer; Colon cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 19 May 2021 New trial record
- 01 May 2021 Results published in the Cancer Immunology Immunotherapy